3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer

Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illus...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-09, Vol.9 (9), p.e108193-e108193
Main Authors: McKinley, Eliot T, Zhao, Ping, Coffey, Robert J, Washington, M Kay, Manning, H Charles
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
Animals
Antineoplastic Agents - therapeutic use
Bioindicators
Biomarkers
Biomedical engineering
Cancer
Cancer therapies
Cancer treatment
Cell Line, Tumor
Cetuximab - therapeutic use
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - diagnostic imaging
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - metabolism
Health aspects
K-Ras protein
Kinases
MAP kinase
Medical imaging
Medical schools
Medicine
Medicine and Health Sciences
Melanoma
Mice
Mice, Nude
Monoclonal antibodies
Oncology
Phosphatidylinositol 3-Kinases - metabolism
Positron emission
Positron emission tomography
Precision medicine
Salvage
Solid tumors
Survival
Targeted cancer therapy
Therapy
Thymidine
Tomography
TOR protein
TOR Serine-Threonine Kinases - metabolism
Tumors
Vultur
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53
cites cdi_FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53
container_end_page e108193
container_issue 9
container_start_page e108193
container_title PloS one
container_volume 9
creator McKinley, Eliot T
Zhao, Ping
Coffey, Robert J
Washington, M Kay
Manning, H Charles
description Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illustrate that [(18)F]-FLT PET, a non-invasive molecular imaging readout of thymidine salvage, closely reflects pro-survival responses to targeted therapy that are mediated by PI3K-mTOR activity. Activation of pro-survival mechanisms forms the basis of numerous modes of resistance. Therefore, we conclude that [(18)F]-FLT PET may serve a novel and potentially critical role to predict tumors that exhibit molecular features that tend to reflect recalcitrance to MAPK-targeted therapy. Though these studies focused on colorectal cancer, we envision that the results may be applicable to other solid tumors as well.
doi_str_mv 10.1371/journal.pone.0108193
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1564387496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A418127356</galeid><doaj_id>oai_doaj_org_article_61f0519b828b457ea625511ec495e8bd</doaj_id><sourcerecordid>A418127356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53</originalsourceid><addsrcrecordid>eNqNk21rFDEQxxdRbK1-A9GFgg8v9kw2T7tvhFJbPSy01OobkZDNzu7lyG3OJFt638CPba69lp70hSxkw-Q3_8xMZrLsJUYTTAT-MHejH5SdLN0AE4RRhWvyKNtNa1nwEpHH9_Y72bMQ5ggxUnH-NNspWUmFwGg3-0PeFp_AXa2KtPmJq-NfxbEdnXdxtlqY1gyQnx1d5GahejP0uYfOgo4hP5uSr8Xi4vS8WEBrVIQ2X3pXhNFfmktlExhSYAHy6PKofA9rIs7Aq-UqN0OunXU-KSVUq0GDf5496ZQN8GLz38u-Hx9dHH4pTk4_Tw8PTgrN6zIWWjekYUw0uCGsQwjVLeMtCNJRSmoCCoHoMC6TqaRUlYwKwKJBWAvOecvIXvb6RndpXZCbIgaJGaekErTmiZjeEK1Tc7n0KXe_kk4ZeW1wvpfKR6MtSI47xHDdVGXVUCZA8ZIxjEHTmkHVtEnr4-a2sUmF0jBEr-yW6PbJYGayd5eSYlEKtg733UbAu98jhCgXJmiwVg3gxuu4eXr5tCR0_x_04ew2VK9SAmboXLpXr0XlAcUVLgVha2ryAJW-FhZGp47rTLJvObzfckhMhKvYqzEEOf12_v_s6Y9t9s09dgbKxllwdowmddc2SG9A7V0IqU_vioyRXA_MbTXkemDkZmCS26v7D3TndDsh5C_JcA9E</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1564387496</pqid></control><display><type>article</type><title>3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>McKinley, Eliot T ; Zhao, Ping ; Coffey, Robert J ; Washington, M Kay ; Manning, H Charles</creator><contributor>Liu, Chunming</contributor><creatorcontrib>McKinley, Eliot T ; Zhao, Ping ; Coffey, Robert J ; Washington, M Kay ; Manning, H Charles ; Liu, Chunming</creatorcontrib><description>Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illustrate that [(18)F]-FLT PET, a non-invasive molecular imaging readout of thymidine salvage, closely reflects pro-survival responses to targeted therapy that are mediated by PI3K-mTOR activity. Activation of pro-survival mechanisms forms the basis of numerous modes of resistance. Therefore, we conclude that [(18)F]-FLT PET may serve a novel and potentially critical role to predict tumors that exhibit molecular features that tend to reflect recalcitrance to MAPK-targeted therapy. Though these studies focused on colorectal cancer, we envision that the results may be applicable to other solid tumors as well.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0108193</identifier><identifier>PMID: 25247710</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>1-Phosphatidylinositol 3-kinase ; Animals ; Antineoplastic Agents - therapeutic use ; Bioindicators ; Biomarkers ; Biomedical engineering ; Cancer ; Cancer therapies ; Cancer treatment ; Cell Line, Tumor ; Cetuximab - therapeutic use ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - diagnostic imaging ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - metabolism ; Health aspects ; K-Ras protein ; Kinases ; MAP kinase ; Medical imaging ; Medical schools ; Medicine ; Medicine and Health Sciences ; Melanoma ; Mice ; Mice, Nude ; Monoclonal antibodies ; Oncology ; Phosphatidylinositol 3-Kinases - metabolism ; Positron emission ; Positron emission tomography ; Precision medicine ; Salvage ; Solid tumors ; Survival ; Targeted cancer therapy ; Therapy ; Thymidine ; Tomography ; TOR protein ; TOR Serine-Threonine Kinases - metabolism ; Tumors ; Vultur</subject><ispartof>PloS one, 2014-09, Vol.9 (9), p.e108193-e108193</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 McKinley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 McKinley et al 2014 McKinley et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53</citedby><cites>FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1564387496/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1564387496?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,25783,27957,27958,37047,37048,44625,53827,53829,75483</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25247710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Liu, Chunming</contributor><creatorcontrib>McKinley, Eliot T</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><creatorcontrib>Coffey, Robert J</creatorcontrib><creatorcontrib>Washington, M Kay</creatorcontrib><creatorcontrib>Manning, H Charles</creatorcontrib><title>3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illustrate that [(18)F]-FLT PET, a non-invasive molecular imaging readout of thymidine salvage, closely reflects pro-survival responses to targeted therapy that are mediated by PI3K-mTOR activity. Activation of pro-survival mechanisms forms the basis of numerous modes of resistance. Therefore, we conclude that [(18)F]-FLT PET may serve a novel and potentially critical role to predict tumors that exhibit molecular features that tend to reflect recalcitrance to MAPK-targeted therapy. Though these studies focused on colorectal cancer, we envision that the results may be applicable to other solid tumors as well.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bioindicators</subject><subject>Biomarkers</subject><subject>Biomedical engineering</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cancer treatment</subject><subject>Cell Line, Tumor</subject><subject>Cetuximab - therapeutic use</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - diagnostic imaging</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Health aspects</subject><subject>K-Ras protein</subject><subject>Kinases</subject><subject>MAP kinase</subject><subject>Medical imaging</subject><subject>Medical schools</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Melanoma</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Phosphatidylinositol 3-Kinases - metabolism</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Precision medicine</subject><subject>Salvage</subject><subject>Solid tumors</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Therapy</subject><subject>Thymidine</subject><subject>Tomography</subject><subject>TOR protein</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><subject>Tumors</subject><subject>Vultur</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk21rFDEQxxdRbK1-A9GFgg8v9kw2T7tvhFJbPSy01OobkZDNzu7lyG3OJFt638CPba69lp70hSxkw-Q3_8xMZrLsJUYTTAT-MHejH5SdLN0AE4RRhWvyKNtNa1nwEpHH9_Y72bMQ5ggxUnH-NNspWUmFwGg3-0PeFp_AXa2KtPmJq-NfxbEdnXdxtlqY1gyQnx1d5GahejP0uYfOgo4hP5uSr8Xi4vS8WEBrVIQ2X3pXhNFfmktlExhSYAHy6PKofA9rIs7Aq-UqN0OunXU-KSVUq0GDf5496ZQN8GLz38u-Hx9dHH4pTk4_Tw8PTgrN6zIWWjekYUw0uCGsQwjVLeMtCNJRSmoCCoHoMC6TqaRUlYwKwKJBWAvOecvIXvb6RndpXZCbIgaJGaekErTmiZjeEK1Tc7n0KXe_kk4ZeW1wvpfKR6MtSI47xHDdVGXVUCZA8ZIxjEHTmkHVtEnr4-a2sUmF0jBEr-yW6PbJYGayd5eSYlEKtg733UbAu98jhCgXJmiwVg3gxuu4eXr5tCR0_x_04ew2VK9SAmboXLpXr0XlAcUVLgVha2ryAJW-FhZGp47rTLJvObzfckhMhKvYqzEEOf12_v_s6Y9t9s09dgbKxllwdowmddc2SG9A7V0IqU_vioyRXA_MbTXkemDkZmCS26v7D3TndDsh5C_JcA9E</recordid><startdate>20140923</startdate><enddate>20140923</enddate><creator>McKinley, Eliot T</creator><creator>Zhao, Ping</creator><creator>Coffey, Robert J</creator><creator>Washington, M Kay</creator><creator>Manning, H Charles</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140923</creationdate><title>3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer</title><author>McKinley, Eliot T ; Zhao, Ping ; Coffey, Robert J ; Washington, M Kay ; Manning, H Charles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bioindicators</topic><topic>Biomarkers</topic><topic>Biomedical engineering</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cancer treatment</topic><topic>Cell Line, Tumor</topic><topic>Cetuximab - therapeutic use</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - diagnostic imaging</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Health aspects</topic><topic>K-Ras protein</topic><topic>Kinases</topic><topic>MAP kinase</topic><topic>Medical imaging</topic><topic>Medical schools</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Melanoma</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Phosphatidylinositol 3-Kinases - metabolism</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Precision medicine</topic><topic>Salvage</topic><topic>Solid tumors</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Therapy</topic><topic>Thymidine</topic><topic>Tomography</topic><topic>TOR protein</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><topic>Tumors</topic><topic>Vultur</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McKinley, Eliot T</creatorcontrib><creatorcontrib>Zhao, Ping</creatorcontrib><creatorcontrib>Coffey, Robert J</creatorcontrib><creatorcontrib>Washington, M Kay</creatorcontrib><creatorcontrib>Manning, H Charles</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McKinley, Eliot T</au><au>Zhao, Ping</au><au>Coffey, Robert J</au><au>Washington, M Kay</au><au>Manning, H Charles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-09-23</date><risdate>2014</risdate><volume>9</volume><issue>9</issue><spage>e108193</spage><epage>e108193</epage><pages>e108193-e108193</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>Competing Interests: The authors have declared that no competing interests exist.</notes><notes>Conceived and designed the experiments: ETM HCM RJC. Performed the experiments: ETM PZ. Analyzed the data: ETM HCM MKW. Wrote the paper: ETM HCM.</notes><abstract>Biomarkers that predict response to targeted therapy in oncology are an essential component of personalized medicine. In preclinical treatment response studies that featured models of wild-type KRAS or mutant BRAF colorectal cancer treated with either cetuximab or vemurafenib, respectively, we illustrate that [(18)F]-FLT PET, a non-invasive molecular imaging readout of thymidine salvage, closely reflects pro-survival responses to targeted therapy that are mediated by PI3K-mTOR activity. Activation of pro-survival mechanisms forms the basis of numerous modes of resistance. Therefore, we conclude that [(18)F]-FLT PET may serve a novel and potentially critical role to predict tumors that exhibit molecular features that tend to reflect recalcitrance to MAPK-targeted therapy. Though these studies focused on colorectal cancer, we envision that the results may be applicable to other solid tumors as well.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25247710</pmid><doi>10.1371/journal.pone.0108193</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2014-09, Vol.9 (9), p.e108193-e108193
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1564387496
source Publicly Available Content Database; PubMed Central
subjects 1-Phosphatidylinositol 3-kinase
Animals
Antineoplastic Agents - therapeutic use
Bioindicators
Biomarkers
Biomedical engineering
Cancer
Cancer therapies
Cancer treatment
Cell Line, Tumor
Cetuximab - therapeutic use
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - diagnostic imaging
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - metabolism
Health aspects
K-Ras protein
Kinases
MAP kinase
Medical imaging
Medical schools
Medicine
Medicine and Health Sciences
Melanoma
Mice
Mice, Nude
Monoclonal antibodies
Oncology
Phosphatidylinositol 3-Kinases - metabolism
Positron emission
Positron emission tomography
Precision medicine
Salvage
Solid tumors
Survival
Targeted cancer therapy
Therapy
Thymidine
Tomography
TOR protein
TOR Serine-Threonine Kinases - metabolism
Tumors
Vultur
title 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T03%3A02%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=3'-Deoxy-3'-%5B18F%5D-Fluorothymidine%20PET%20imaging%20reflects%20PI3K-mTOR-mediated%20pro-survival%20response%20to%20targeted%20therapy%20in%20colorectal%20cancer&rft.jtitle=PloS%20one&rft.au=McKinley,%20Eliot%20T&rft.date=2014-09-23&rft.volume=9&rft.issue=9&rft.spage=e108193&rft.epage=e108193&rft.pages=e108193-e108193&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0108193&rft_dat=%3Cgale_plos_%3EA418127356%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-ccb3b557b1b35f0009d56de73f44393ea0e7f112de7244a2547e17b01c7666d53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1564387496&rft_id=info:pmid/25247710&rft_galeid=A418127356&rfr_iscdi=true